This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation

Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) Trial

View larger version (16K): [in a new window]   Figure 1 Inhibition of platelet aggregation in response to adenosine diphosphate (ADP) and thrombin receptor agonist peptide (TRAP) at steady state, 6 to 18 h after study drug bolus. Results are expressed as medians with interquartile ranges.